We envision a world free of neurodegenerative diseases.

X-tosis is dedicated to revolutionizing the treatment of neurodegenerative diseases, starting with Alzheimer’s and extending to other conditions. Our mission is to develop innovative solutions that target the underlying causes, offering hope to patients and their families.

About Us

X-tosis, founded in 2024, is a precision-medicine biotechnology company developing first-in-class mitochondrial therapeutics for neurodegenerative diseases. Our approach builds on more than two decades of foundational research led by Professor Varda Shoshan-Barmatz, whose pioneering discoveries in mitochondrial dysfunction and apoptosis established VDAC1 as a critical regulator of neuronal survival.

At X-tosis, we are advancing a new therapeutic strategy that targets the root drivers of neurodegeneration. Our XTS compounds inhibit VDAC1 oligomerization, restoring mitochondrial function and preventing the apoptosis triggered by amyloid-beta, inflammation, and other cellular stressors. By intervening upstream in the neurodegeneration cascade, we aim to slow or halt disease progression rather than simply manage symptoms.

Our mission is to transform treatment for Alzheimer’s disease, Parkinson’s disease, ALS, and related conditions by protecting brain cells and preserving function. Supported by a team of experienced scientists, industry leaders, and global collaborators, X-tosis is translating decades of research into a precision platform designed to deliver disease-modifying therapies and improve patients’ lives.

Our Mission

X-tosis is committed to transforming the treatment of neurodegenerative, and other diseases, by leveraging the potential of mitochondrial biology. Our mission is to tirelessly discover, develop, and deliver innovative, therapies and diagnostics that target mitochondria, aiming to restore cellular health and prevent neurodegeneration.

Our Values

At X-tosis, our core values are the bedrock of every decision, action, and interaction.. They shape our culture, drive our strategy, and reinforce our unwavering commitment to our mission.

X-tosis Core Values:

Patient-Centricity: Every decision, every discovery, every effort begins and ends with the patient's well-being in mind.
Scientific Rigor & Innovation: We commit to the highest standards of scientific excellence, embracing curiosity and creative problem-solving to push the boundaries of mitochondrial medicine.
Integrity & Respect: We operate with unwavering honesty, transparency, and respect for all stakeholders including colleagues, partners, and the communities we serve.
Accountability & Drive: We take ownership of our commitments, work with exceptional dedication, and strive for excellence in all that we do to achieve our ambitious goals.
Fiscal Prudence: We are diligent stewards of our resources, ensuring responsible financial management to maximize impact for patients and value for our stakeholders.

Value Proposition

Preclinical Success

Our lead XTS compounds have demonstrated robust efficacy in Alzheimer’s and Parkinson’s preclinical models, including reductions in neuronal loss, improvements in cognitive function, restoration of mitochondrial activity, and mitigation of inflammation. These findings support the potential for disease-modifying therapeutic impact.

Unique Target

X-tosis targets mitochondrial dysfunction, the upstream driver of neurodegeneration, by inhibiting VDAC1 oligomerization. This novel, first-in-class approach protects neurons against apoptosis and cellular stress, offering a fundamentally different strategy from symptomatic or downstream protein-targeting therapies.

Growing Market

Neurodegenerative diseases such as Alzheimer’s and Parkinson’s affect millions worldwide, yet available treatments offer limited benefit and do not address the underlying biology. X-tosis’s mitochondrial-centric, precision-medicine approach addresses this urgent unmet need with the potential for true disease modification.

Strong IP Position

Our technology is protected by a robust patent portfolio extending through at least 2036, covering VDAC1-targeting compounds and their use across multiple neurodegenerative and inflammation-driven conditions. This IP foundation enables significant commercial and clinical expansion opportunities.

Strong Leadership and Scientific Team

X-tosis is led by a seasoned team with deep experience in drug development, neuroscience, mitochondrial biology, and clinical research. Our advisory board and global research collaborations strengthen our scientific platform and accelerate development of XTS compounds toward the clinic.